Last $72.38 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:04 PM 04/22/14 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Open
$73.10
Previous Close
$73.15
Day High
$73.38
Day Low
$72.34
52 Week High
03/27/14 - $75.68
52 Week Low
10/2/13 - $62.80
Market Cap
39.2B
Average Volume 10 Days
3.1M
EPS TTM
$4.82
Shares Outstanding
540.9M
EX-Date
03/5/14
P/E TM
15.0x
Dividend
$1.96
Dividend Yield
2.71%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX)

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.

61,000 Employees
Last Reported Date: 02/21/14
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $687.7K
Corporate Vice President and President of Int...
Total Annual Compensation: $771.2K
Corporate Vice President and President of Bio...
Total Annual Compensation: $742.3K
Compensation as of Fiscal Year 2013.

baxter international inc (BAX) Key Developments

Baxter International Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Second Quarter of 2014 and Reaffirms Earnings Guidance for the Full Year of 2014

Baxter International Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported pretax income of $709 million, net income of $556 million or $1.01 diluted per share on net sales of $3,951 million against pretax income of $693 million, net income of $552 million or $1.00 diluted per share on net sales of $3,448 million for the same period a year ago. Adjusted pre-tax income was $829 million, adjusted net income of $652 million or $1.19 per share against adjusted pre-tax income was $763 million, adjusted net income of $601 million or $1.09 per share for the same period a year ago. Cash flows from operations was $559 million against $386 million for the same period a year ago. Capital expenditures was $421 million against $292 million for the same period a year ago. The company provides earnings guidance for the second quarter of 2014 and reaffirms earnings guidance for the full year of 2014. For the second quarter of 2014, the company expects sales growth of approximately 12% to 13%, excluding the impact of foreign currency. Baxter expects earnings, before special items, of $1.18 to $1.22 per diluted share in the second quarter. The second quarter 2014 earnings guidance excludes approximately $0.07 per diluted share of projected intangible asset amortization expense. Reconciling for the inclusion of these items results in GAAP (Generally Accepted Accounting Principles) earnings of $1.11 to $1.15 per diluted share for the second quarter. Baxter expects sales growth for full-year 2014 of 9% to 10%, before the impact of foreign exchange. Also for the full year, Baxter expects earnings, before special items, of $5.05 to $5.25 per diluted share and cash flows from operations of approximately $3.5 billion. The full year 2014 earnings guidance excludes $0.38 per diluted share of special items comprising $0.18 per diluted share of items recorded in the first quarter, and projected intangible asset amortization expense of $0.20 per diluted share for the remainder of the year. Reconciling for the inclusion of these items results in GAAP (Generally Accepted Accounting Principles) earnings of $4.67 to $4.87 per diluted share for the full year 2014.

Baxter International Corporation to Invest $1 Billion to Construct 1 Million-Square-Foot Plasma Fractionation Facility in Georgia

Baxter International Corporation decided to invest $1 billion to construct a 1 million-square-foot plasma fractionation facility with purification and fill/finish suites in Covington, Georgia. In support of the massive project, now under construction, the state is building the $14 million Georgia BioScience Training Center adjacent to the new plant.

Baxter International Inc. Announces Top Line Results from a Phase 3 Clinical Trial Evaluating the Safety, Efficacy and Pharmacokinetics of BAX 111

Baxter International Inc. announced top line results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics of BAX 111. BAX 111 is a recombinant von Willebrand factor under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder. The study of BAX 111, the first recombinant treatment in clinical development for this condition, met its primary efficacy endpoint, as all patients achieved pre-specified success in the on-demand treatment of bleeding events. The Phase 3 multicenter, open-label clinical trial assessed the safety, efficacy and pharmacokinetics of BAX 111 administered together with ADVATE or as a stand-alone therapeutic agent in the on-demand treatment of 37 patients with severe von Willebrand disease at trial sites in the United States, Europe, Australia, Japan, Russia and India. The primary endpoint was the number of patients experiencing successful treatment for bleeding episodes. Secondary endpoints included additional efficacy and safety measures, pharmacokinetics and health-related quality of life.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $72.38 USD 0.00

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covidien PLC $70.59 USD 0.00
Danone SA €52.15 EUR -0.37
Kimberly-Clark Corp $108.40 USD 0.00
Stryker Corp $78.74 USD 0.00
Teva Pharmaceutical Industries Ltd $51.45 USD 0.00
View Industry Companies
 

Industry Analysis

BAX

Industry Average

Valuation BAX Industry Range
Price/Earnings 19.9x
Price/Sales 2.5x
Price/Book 4.7x
Price/Cash Flow 19.6x
TEV/Sales 1.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.